The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Association Between BRCA Status and Triple-Negative Breast Cancer: A Meta-Analysis
Open accessAbstract
Triple-negative breast cancer (TNBC) is a subtype of aggressive breast cancer and characterized by a lack of the expression of estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2. BRCA genes are tumor-suppressor genes that are involved in DNA damage repair and mutations of BRCA genes may increase the risk of developing breast cancer and/or ovarian cancer due to defective DNA repair mechanisms. However, the relationship between BRCA status and TNBC needs to be further investigated and validated. The aim of this meta-analysis was to evaluate the association between BRCA status and TNBC. We systematically searched the electronic databases of MEDLINE (PubMed), Embase and Cochrane Library to identify relevant publications from April, 1959 to November, 2017. The data from the studies were examined by a meta-analysis using STATA software to calculate the odds ratio (OR) with 95% confidence interval (CI) by fixed-effect and random-effect models. We identified 16 qualified studies from 527 publications with 46,870 breast cancer patients including 868 BRCA1 mutations (BRCA1Mut) carriers, 739 BRCA2 mutations (BRCA2Mut) carriers, and 45,263 non-carriers. The results showed that breast cancer patients with BRCA1Mut carriers were more likely to have TNBC than those of BRCA2Mut carriers (OR: 3.292; 95% CI: 2.773-3.909) or non-carriers (OR: 8.889; 95% CI: 6.925-11.410). Furthermore, high expression of nuclear grade and large tumor burden (> 2 cm) were significantly more common in breast cancer patients with BRCA1Mut carriers than those of BRCA2Mut carriers (OR: 2.663; 95% CI: 1.731-4.097; P = 0.211) or non-carriers (OR: 1.577; 95% CI: 1.067-2.331; P = 0.157). The data suggest that breast cancer patients with BRCA1Mut are more likely to have TNBC, high nuclear grade and larger tumor burden.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Evaluating non-randomised intervention studies
Deeks, J., Dinnes, J., D'Amico, R., Sowden, A., Sakarovitch, C., Song, F., Petticrew, M., & Altman, D. (2003) · Health Technology Assessment · doi:10.3310/hta7270 · Cited by 2,907
Yoshida, K., & Miki, Y. (2004) · Cancer Science · doi:10.1111/j.1349-7006.2004.tb02195.x · Cited by 753 · cited 1×
“The data indicate that there was no obvious indication of publication bias. damage (Yoshida and Miki, 2004).”
BackgroundTriple-negative breast cancer: epidemiological considerations and recommendations
Boyle, P. (2012) · Annals of Oncology · doi:10.1093/annonc/mds187 · Cited by 593
Catteau, A., Harris, W. H., Xu, C.-F., & Solomon, E. (1999) · Oncogene · doi:10.1038/sj.onc.1202509 · Cited by 354
Cited by
Breast Cancer—Epidemiology, Classification, Pathogenesis and Treatment (Review of Literature)
Smolarz, B., Nowak, A. Z., & Romanowicz, H. (2022) · Cancers · doi:10.3390/cancers14102569 · Cited by 587
Breast Cancer Treatments: Updates and New Challenges
Burguin, A., Diorio, C., & Durocher, F. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11080808 · Cited by 488
Bardia, A., Tolaney, S. M., Punie, K., Loirat, D., Oliveira, M., Kalinsky, K., Zelnak, A., Aftimos, P., Dalenc, F., Sardesai, S., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.06.002 · Cited by 326
Metadata
- Authors
- Chen, H., Wu, J., Zhang, Z., Tang, Y., Li, X., Liu, S., Cao, S., & Li, X.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2018-08-21
- Volume
- 9
- Pages
- 909-909
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W2884256577
- Cited by
- 188
- References
- 4
- FWCI
- 2.32
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.